A Randomized, Open-label, Two-arm, Parallel Group, Single Dose Study to Assess the Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Autoimmune disorders; Inflammation; Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Baxalta
- 11 May 2016 Status changed from recruiting to active, no longer recruiting.
- 16 Feb 2016 New trial record
- 11 Feb 2016 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.